 | • レポートコード：D005-00867 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、関節リウマチ（RA）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。関節リウマチ（RA）薬の種類別市場規模（経口、注射、外用）、用途別市場規模（医療、パーソナルケア）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AbbVie、UCB、Amgen, Inc.、Roche、Bristol-Myers Squibb、Johnson & Johnson、Sanofi、Merck、Pfizer、GlaxoSmithKline、Abbott Laboratories、Teva Pharmaceutical ・地域別グローバル市場分析 2015年-2020年 ・関節リウマチ（RA）薬の北米市場（アメリカ、カナダ、メキシコ） ・関節リウマチ（RA）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・関節リウマチ（RA）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・関節リウマチ（RA）薬の南米市場（ブラジル、アルゼンチン） ・関節リウマチ（RA）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：経口、注射、外用 ・用途別分析：医療、パーソナルケア ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Rheumatoid Arthritis (RA) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.4% in the forecast period of 2020 to 2025 and will expected to reach USD 21300 million by 2025, from USD 18600 million in 2019.
The Rheumatoid Arthritis (RA) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Rheumatoid Arthritis (RA) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Rheumatoid Arthritis (RA) Drugs market has been segmented into:
Oral
Injection
External
By Application, Rheumatoid Arthritis (RA) Drugs has been segmented into:
Medical Care
Personal Care
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Rheumatoid Arthritis (RA) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Rheumatoid Arthritis (RA) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Rheumatoid Arthritis (RA) Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Rheumatoid Arthritis (RA) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Rheumatoid Arthritis (RA) Drugs Market Share Analysis
Rheumatoid Arthritis (RA) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Rheumatoid Arthritis (RA) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Rheumatoid Arthritis (RA) Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Rheumatoid Arthritis (RA) Drugs are:
AbbVie
UCB
Amgen, Inc.
Roche
Bristol-Myers Squibb
Johnson & Johnson
Sanofi
Merck
Pfizer
GlaxoSmithKline
Abbott Laboratories
Teva Pharmaceutical
Table of Contents
1 Rheumatoid Arthritis (RA) Drugs Market Overview
1.1 Product Overview and Scope of Rheumatoid Arthritis (RA) Drugs
1.2 Classification of Rheumatoid Arthritis (RA) Drugs by Type
1.2.1 Global Rheumatoid Arthritis (RA) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type in 2019
1.2.3 Oral
1.2.4 Injection
1.2.5 External
1.3 Global Rheumatoid Arthritis (RA) Drugs Market by Application
1.3.1 Overview: Global Rheumatoid Arthritis (RA) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Medical Care
1.3.3 Personal Care
1.4 Global Rheumatoid Arthritis (RA) Drugs Market by Regions
1.4.1 Global Rheumatoid Arthritis (RA) Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Rheumatoid Arthritis (RA) Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Rheumatoid Arthritis (RA) Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Rheumatoid Arthritis (RA) Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Rheumatoid Arthritis (RA) Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Rheumatoid Arthritis (RA) Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Rheumatoid Arthritis (RA) Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AbbVie SWOT Analysis
2.1.4 AbbVie Product and Services
2.1.5 AbbVie Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 UCB
2.2.1 UCB Details
2.2.2 UCB Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 UCB SWOT Analysis
2.2.4 UCB Product and Services
2.2.5 UCB Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Amgen, Inc.
2.3.1 Amgen, Inc. Details
2.3.2 Amgen, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Amgen, Inc. SWOT Analysis
2.3.4 Amgen, Inc. Product and Services
2.3.5 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bristol-Myers Squibb SWOT Analysis
2.5.4 Bristol-Myers Squibb Product and Services
2.5.5 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Johnson & Johnson SWOT Analysis
2.6.4 Johnson & Johnson Product and Services
2.6.5 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Sanofi SWOT Analysis
2.7.4 Sanofi Product and Services
2.7.5 Sanofi Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Merck SWOT Analysis
2.8.4 Merck Product and Services
2.8.5 Merck Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Pfizer SWOT Analysis
2.9.4 Pfizer Product and Services
2.9.5 Pfizer Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 GlaxoSmithKline
2.10.1 GlaxoSmithKline Details
2.10.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 GlaxoSmithKline SWOT Analysis
2.10.4 GlaxoSmithKline Product and Services
2.10.5 GlaxoSmithKline Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 Abbott Laboratories
2.11.1 Abbott Laboratories Details
2.11.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Abbott Laboratories SWOT Analysis
2.11.4 Abbott Laboratories Product and Services
2.11.5 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.12 Teva Pharmaceutical
2.12.1 Teva Pharmaceutical Details
2.12.2 Teva Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Teva Pharmaceutical SWOT Analysis
2.12.4 Teva Pharmaceutical Product and Services
2.12.5 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Rheumatoid Arthritis (RA) Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Rheumatoid Arthritis (RA) Drugs Players Market Share
3.2.2 Top 10 Rheumatoid Arthritis (RA) Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Rheumatoid Arthritis (RA) Drugs Revenue and Market Share by Regions
4.2 North America Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
5 North America Rheumatoid Arthritis (RA) Drugs Revenue by Countries
5.1 North America Rheumatoid Arthritis (RA) Drugs Revenue by Countries (2015-2020)
5.2 USA Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
6 Europe Rheumatoid Arthritis (RA) Drugs Revenue by Countries
6.1 Europe Rheumatoid Arthritis (RA) Drugs Revenue by Countries (2015-2020)
6.2 Germany Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
6.4 France Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue by Countries
7.1 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue by Countries (2015-2020)
7.2 China Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
7.5 India Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
8 South America Rheumatoid Arthritis (RA) Drugs Revenue by Countries
8.1 South America Rheumatoid Arthritis (RA) Drugs Revenue by Countries (2015-2020)
8.2 Brazil Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Rheumatoid Arthritis (RA) Drugs by Countries
9.1 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Rheumatoid Arthritis (RA) Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Rheumatoid Arthritis (RA) Drugs Market Forecast by Type (2019-2024)
10.3 Oral Revenue Growth Rate (2015-2025)
10.4 Injection Revenue Growth Rate (2015-2025)
10.5 External Revenue Growth Rate (2015-2025)
11 Global Rheumatoid Arthritis (RA) Drugs Market Segment by Application
11.1 Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application (2015-2020)
11.2 Rheumatoid Arthritis (RA) Drugs Market Forecast by Application (2019-2024)
11.3 Medical Care Revenue Growth (2015-2020)
11.4 Personal Care Revenue Growth (2015-2020)
12 Global Rheumatoid Arthritis (RA) Drugs Market Size Forecast (2021-2025)
12.1 Global Rheumatoid Arthritis (RA) Drugs Market Size Forecast (2021-2025)
12.2 Global Rheumatoid Arthritis (RA) Drugs Market Forecast by Regions (2021-2025)
12.3 North America Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
12.6 South America Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Rheumatoid Arthritis (RA) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Rheumatoid Arthritis (RA) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Rheumatoid Arthritis (RA) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AbbVie Corporate Information, Location and Competitors
Table 6. AbbVie Rheumatoid Arthritis (RA) Drugs Major Business
Table 7. AbbVie Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 8. AbbVie SWOT Analysis
Table 9. AbbVie Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 10. AbbVie Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. UCB Corporate Information, Location and Competitors
Table 12. UCB Rheumatoid Arthritis (RA) Drugs Major Business
Table 13. UCB Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2018-2019)
Table 14. UCB SWOT Analysis
Table 15. UCB Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 16. UCB Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Amgen, Inc. Corporate Information, Location and Competitors
Table 18. Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Major Business
Table 19. Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 20. Amgen, Inc. SWOT Analysis
Table 21. Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 22. Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Roche Corporate Information, Location and Competitors
Table 24. Roche Rheumatoid Arthritis (RA) Drugs Major Business
Table 25. Roche Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 26. Roche SWOT Analysis
Table 27. Roche Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 28. Roche Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 30. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Major Business
Table 31. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Bristol-Myers Squibb SWOT Analysis
Table 33. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 34. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Johnson & Johnson Corporate Information, Location and Competitors
Table 36. Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Major Business
Table 37. Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Johnson & Johnson SWOT Analysis
Table 39. Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 40. Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Sanofi Corporate Information, Location and Competitors
Table 42. Sanofi Rheumatoid Arthritis (RA) Drugs Major Business
Table 43. Sanofi Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 44. Sanofi SWOT Analysis
Table 45. Sanofi Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 46. Sanofi Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Merck Corporate Information, Location and Competitors
Table 48. Merck Rheumatoid Arthritis (RA) Drugs Major Business
Table 49. Merck Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 50. Merck SWOT Analysis
Table 51. Merck Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 52. Merck Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Pfizer Corporate Information, Location and Competitors
Table 54. Pfizer Rheumatoid Arthritis (RA) Drugs Major Business
Table 55. Pfizer Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 56. Pfizer SWOT Analysis
Table 57. Pfizer Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 58. Pfizer Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. GlaxoSmithKline Corporate Information, Location and Competitors
Table 60. GlaxoSmithKline Rheumatoid Arthritis (RA) Drugs Major Business
Table 61. GlaxoSmithKline Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 62. GlaxoSmithKline SWOT Analysis
Table 63. GlaxoSmithKline Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 64. GlaxoSmithKline Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Abbott Laboratories Corporate Information, Location and Competitors
Table 66. Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Major Business
Table 67. Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 68. Abbott Laboratories SWOT Analysis
Table 69. Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 70. Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Teva Pharmaceutical Corporate Information, Location and Competitors
Table 72. Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Major Business
Table 73. Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Total Revenue (USD Million) (2017-2018)
Table 74. Teva Pharmaceutical SWOT Analysis
Table 75. Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Product and Solutions
Table 76. Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) by Players (2015-2020)
Table 78. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Players (2015-2020)
Table 79. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) by Regions (2015-2020)
Table 80. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Regions (2015-2020)
Table 81. North America Rheumatoid Arthritis (RA) Drugs Revenue by Countries (2015-2020)
Table 82. North America Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Table 83. Europe Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 84. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 85. South America Rheumatoid Arthritis (RA) Drugs Revenue by Countries (2015-2020)
Table 86. South America Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Table 87. Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 88. Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Table 89. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) by Type (2015-2020)
Table 90. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Type (2015-2020)
Table 91. Global Rheumatoid Arthritis (RA) Drugs Revenue Forecast by Type (2021-2025)
Table 92. Global Rheumatoid Arthritis (RA) Drugs Revenue by Application (2015-2020)
Table 93. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Application (2015-2020)
Table 94. Global Rheumatoid Arthritis (RA) Drugs Revenue Forecast by Application (2021-2025)
Table 95. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Rheumatoid Arthritis (RA) Drugs Picture
Figure 2. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type in 2019
Figure 3. Oral Picture
Figure 4. Injection Picture
Figure 5. External Picture
Figure 6. Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application in 2019
Figure 7. Medical Care Picture
Figure 8. Personal Care Picture
Figure 9. Global Rheumatoid Arthritis (RA) Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Rheumatoid Arthritis (RA) Drugs Revenue Market Share in 2019
Figure 18. Global Top 10 Players Rheumatoid Arthritis (RA) Drugs Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Regions (2015-2020)
Figure 22. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Regions in 2018
Figure 23. North America Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 24. Europe Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 26. South America Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 28. North America Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Figure 29. North America Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries in 2019
Figure 30. USA Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 31. Canada Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 33. Europe Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries in 2019
Figure 35. Germany Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 36. UK Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 37. France Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 38. Russia Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 39. Italy Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries in 2019
Figure 42. China Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Japan Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 44. Korea Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 45. India Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 47. South America Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Figure 48. South America Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries in 2019
Figure 49. Brazil Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 54. UAE Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Rheumatoid Arthritis (RA) Drugs Revenue and Growth Rate (2015-2020)
Figure 57. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Type (2015-2020)
Figure 58. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Type in 2019
Figure 59. Global Rheumatoid Arthritis (RA) Drugs Market Share Forecast by Type (2021-2025)
Figure 60. Global Oral Revenue Growth Rate (2015-2020)
Figure 61. Global Injection Revenue Growth Rate (2015-2020)
Figure 62. Global External Revenue Growth Rate (2015-2020)
Figure 63. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Application (2015-2020)
Figure 64. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Application in 2019
Figure 65. Global Rheumatoid Arthritis (RA) Drugs Market Share Forecast by Application (2021-2025)
Figure 66. Global Medical Care Revenue Growth Rate (2015-2020)
Figure 67. Global Personal Care Revenue Growth Rate (2015-2020)
Figure 68. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Rheumatoid Arthritis (RA) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
Figure 72. Europe Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
Figure 74. South America Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
経口薄膜薬の世界市場レポート2020 Market Analysis and Insights: Global Oral Thin Film Drugs Market The global Oral Thin Film Drugs market was valued at US$ 1975.8 million in 2019 and will reach US$ 3496.4 million by the end of 2026, growing at a CAGR of 8.4% during 2020-2026. Global Oral Thin Film Drugs Scope and Market Size The glo…- 口唇ヘルペス（口腔ヘルペス）薬の世界市場レポート2020 Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the …
- エクセナチド薬の世界市場レポート2020 A recently published report by QY Research titled Global Exenatide Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate da…
- 口腔粘膜炎薬の世界市場レポート2020 Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemoth…
- リンパ腫薬の世界市場レポート2020 Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the body. When you have lymphoma, lymphocytes change and grow out of control. The China average price of Lymphoma D…